GAD2 and diabetes mellitus: The recently described electrochemiluminescence assays for IAA and GADA and substituting N-terminally truncated GAD65 (95–585) for full-length GAD in the harmonised radiobinding assay have been shown to improve disease specificity and more accurately discriminate risk of progression to diabetes in single autoantibody positive individuals [26–28].